A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Completed · Phase 2 · Has a placebo group

Conditions studied: Relapsing-Remitting Multiple Sclerosis

In brief

To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.

Key facts

Study ID
NCT00882999
Run by
Eli Lilly and Company
People needed
245
Starts
2009-04-01
Expected to finish
2012-06-01
Last updated by the study team
2018-11-15

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.